ArticleResearch and practice in thrombosis and haemostasis2026
Comparison of monthly bleeding rates after direct oral anticoagulant initiation for venous thromboembolism and atrial fibrillation.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The first month after direct oral anticoagulants: a window of vulnerability.Research and practice in thrombosis and haemostasis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Background: Direct oral anticoagulants (DOACs) are commonly used for the treatment of atrial fibrillation (AF) and venous thromboembolism (VTE) but increase the risk of bleeding. Objectives: We aimed to evaluate the distribution of bleeding events after anticoagulant initiation. Methods: Adult patients in the Michigan Anticoagulation Quality Improvement Initiative registry on DOAC for AF or VTE were followed from anticoagulant start to identify any bleeding event within 12 months. The primary outcome was any bleeding; secondary outcomes were bleeding subtypes. Monthly event rates were compared by Poisson and proportion tests. Results: A total of 2663 patients (mean age 66.9 years, 49% male sex [as recorded in the electronic health record], 72.1% AF) who were starting DOACs were followed. Bleeding event rates were highest after anticoagulant initiation. For VTE, patients experienced 110, 55, and 36 bleeding events per 100 patient-years the first 3 months of anticoagulation, respectively. For AF, patients experienced 66, 43, and 33 bleeding events per 100 patient-years the first 3 months of anticoagulation, respectively. After adjustment for covariates, bleeding was higher for patients with VTE compared with AF, with 51 vs 34 bleeds per 100 patient-years (rate ratio, 0.68; 95% CI, 0.58-0.80; Conclusion: Bleeding rates were highest during the first 3 months of oral anticoagulation; bleeding was higher for patients with VTE compared with AF. These findings emphasize the need for careful management and monitoring after DOAC initiation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.